Ovarian low malignant potential tumours, also known as borderline ovarian tumours, represent an unusual group of ovarian growths that sit somewhere between completely harmless and fully cancerous, offering patients an excellent chance of recovery while requiring careful medical attention and long-term monitoring.

Understanding Ovarian Low Malignant Potential Tumours

An ovarian low malignant potential tumour is a disease in which abnormal cells form in the tissue covering the ovary. These tumours have characteristics that place them in a unique medical category. While they contain abnormal cells that have the potential to become cancer, they usually do not progress to full malignancy. This disease typically remains confined to the ovary itself, though it can occasionally spread to other areas^[1].

The ovaries are a pair of almond-sized organs in the female reproductive system, located in the pelvis on either side of the uterus. They produce eggs and female hormones that regulate reproductive cycles. When a tumour develops in one ovary, doctors must carefully examine the other ovary as well, since disease can sometimes affect both sides^[1].

What makes these tumours particularly noteworthy is their behaviour. Unlike aggressive cancers, ovarian low malignant potential tumours usually grow slowly and stay inside the ovary. The tissue covering the outside of the ovary is where these growths typically begin. When doctors describe these tumours to patients, they often emphasize that hearing the word “tumour” does not automatically mean cancer. These particular growths may become cancerous, but this transformation is rare. Most cases are discovered and treated successfully before any such change occurs^[2].

Who Gets These Tumours and How Often

Borderline ovarian tumours account for approximately fifteen percent of all epithelial ovarian cancers. This means that out of every 100 women diagnosed with ovarian tumours of this type, about 15 will have the borderline variety rather than fully invasive cancer^[8][12].

One of the most encouraging aspects of this disease is that nearly seventy-five percent of these tumours are discovered at stage I, meaning they are found early when the disease is still confined to the ovary. This early detection contributes significantly to the excellent survival rates associated with borderline tumours^[8][12].

Borderline ovarian tumours behave differently from invasive ovarian cancers in terms of who they affect. These tumours typically appear in younger women, often during their forties. This is notably earlier than invasive ovarian carcinomas, which tend to affect older women. The earlier age of diagnosis has important implications, particularly regarding fertility and treatment decisions^[7][13].

Research indicates that borderline ovarian tumours make up nearly twenty percent of ovarian epithelial cancers. The prognosis for patients with these tumours is excellent regardless of the stage at diagnosis. Long-term studies tracking patients over many years have demonstrated survival rates of ninety-seven percent at five years, ninety-five percent at ten years, ninety-two percent at fifteen years, and eighty-nine percent at twenty years for patients with borderline tumours across all stages^[8].

What Causes Borderline Ovarian Tumours

The exact causes of ovarian low malignant potential tumours remain unknown to medical science. Doctors and researchers have not identified specific reasons why some women develop these growths while others do not. This lack of understanding about causation is common with many ovarian conditions and continues to be an area of active research^[2][14].

What researchers have discovered is that borderline ovarian tumours do not appear to have a hereditary component. This means they are not typically passed down through families in the way that some cancers are. This finding distinguishes borderline tumours from certain invasive ovarian cancers, which can have strong genetic links^[7][13].

Recent molecular research has provided some insight into how these tumours develop. The molecular changes found in borderline ovarian tumours suggest they belong to what doctors call “type I ovarian tumours,” which includes low-grade ovarian carcinomas. This classification helps doctors understand the biological behaviour of these growths and how they differ from more aggressive tumour types^[12].

Risk Factors

Although the direct causes remain unclear, certain factors have been linked to an increased risk of developing borderline ovarian tumours. Understanding these risk factors can help women and their doctors make informed decisions about monitoring and prevention strategies.

Fertility treatment stands out as a notable risk factor. Women who used fertility drugs for more than one year without successfully becoming pregnant appear to have a higher risk of developing these tumours. The connection between fertility drugs and borderline tumours suggests that hormonal factors may play a role in tumour development, though the exact mechanism is not fully understood^[2].

Women who never become pregnant may also face an elevated risk. This association mirrors patterns seen with other ovarian conditions and suggests that pregnancy might offer some protective effect against tumour development. The biological reasons for this protection are thought to relate to hormonal changes during pregnancy and the temporary pause in ovulation^[2].

Additional factors that may influence risk include smoking, oral contraceptive use, age at first menstruation, age at first pregnancy and delivery, and age at menopause. These factors all relate to a woman’s reproductive and hormonal history, supporting the idea that hormonal influences play a significant role in tumour development^[14].

Having a family history of ovarian cancer may increase risk, even though borderline tumours themselves do not appear to be hereditary. This suggests that some underlying genetic or familial factors might create vulnerability to various types of ovarian growths^[14].

Symptoms and Warning Signs

One of the challenges with borderline ovarian tumours is that they may not cause noticeable symptoms in their early stages. A woman can have a tumour and not realize it for some time. This silent nature of early disease emphasizes the importance of regular medical check-ups and paying attention to any changes in your body^[1][14].

When symptoms do appear, they often involve abdominal or pelvic discomfort. Women might experience pain or pressure in the pelvis or abdomen. Some describe a sensation of fullness or swelling in the stomach area. These feelings can be vague and may come and go, which can make them easy to dismiss or attribute to other causes^[1][5].

Gastrointestinal symptoms are common and can be particularly confusing because they mimic digestive problems. Women with borderline ovarian tumours may notice bloating, gas, or constipation. They might feel full soon after starting to eat, even when consuming small amounts of food. Some experience more frequent bowel movements than usual. Because these symptoms are so similar to common digestive issues, many women and even some doctors may initially think the problem lies with the stomach or intestines rather than the ovaries^[1][5].

Changes in urinary habits can also occur. Women might find themselves needing to urinate more frequently than before. This happens because a growing tumour can put pressure on the bladder^[5].

Less commonly, women may experience vaginal bleeding that is unrelated to their menstrual cycle, or they might have pain during or after sexual intercourse. These symptoms warrant immediate medical attention^[5].

Prevention Strategies

Because the exact causes of borderline ovarian tumours are not known, specific prevention strategies are limited. However, understanding risk factors can help women make informed choices about their reproductive and general health.

The sources provided do not contain detailed information about specific prevention measures for borderline ovarian tumours. This reflects the current state of medical knowledge, where prevention focuses more on early detection rather than preventing tumour formation entirely.

How the Body Changes with Borderline Tumours

Understanding what happens in the body when a borderline ovarian tumour develops helps explain why symptoms occur and why treatment works the way it does. These tumours represent a unique biological state that differs from both benign growths and aggressive cancers.

Borderline ovarian tumours are characterized by abnormal cell growth in the tissue covering the ovary. Unlike benign cysts, which contain completely normal cells that simply grow too much, borderline tumours contain cells with abnormal features when examined under a microscope. These cells show changes in their structure and organization that pathologists can identify. However, unlike invasive cancer cells, borderline tumour cells do not aggressively invade surrounding tissues or break through boundaries to spread widely^[5].

The tumours typically consist of cystic structures with specific characteristics. Serous borderline tumours, the most common type, are filled with fluid and show a distinctive hierarchical branching pattern when examined microscopically. This pattern differs from what doctors see in completely benign cysts or normal tissue. Mucinous tumours, the second most common type, are filled with mucus-like fluid^[5].

When borderline tumours do spread beyond the ovary, they form what doctors call “implants” on other surfaces in the abdomen. These implants can be classified as either invasive or noninvasive based on their microscopic appearance. Noninvasive implants sit on the surface of tissues without infiltrating deeply. Invasive implants show more aggressive features and can penetrate into underlying tissues. The type of implant present is one of the major factors that predicts how the disease will behave^[12][13].

An important biological feature of borderline tumours is their slow growth rate. These tumours typically develop and enlarge much more gradually than invasive cancers. This slow progression contributes to the good prognosis and explains why many tumours are caught at an early stage^[2].

The molecular biology of borderline tumours shows specific genetic changes that distinguish them from other ovarian conditions. These molecular alterations help explain why borderline tumours behave the way they do—more aggressive than benign cysts but less dangerous than invasive cancers. Some borderline tumours can transform into low-grade serous carcinomas, but this progression is uncommon^[12].